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ABSTRACT
Objectives: To develop and validate an instrument to
measure health-related quality of life (HRQOL) speciﬁc to
patients with allergic rhinitis (AR) and primarily for use in
Spanish and Spanish-speaking populations.
Methods: An initial item pool was generated from literature
review, focus groups with AR patients, and consultations
with clinical experts. Item reduction was performed using
clinimetric and psychometric approaches after administra-
tion of the item pool to 400 AR patients. The resulting
instrument’s internal consistency, test–retest (2–4 weeks) reli-
ability, known groups and convergent validity, and sensitivity
to change were tested in a longitudinal, observational, mul-
ticenter study in 210 AR patients who also completed the
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).
Results: The new questionnaire took a mean (SD) of 7.1
(5.4) minutes to answer. Floor and ceiling effects were less
than 15% on all dimensions. Cronbach’s alpha values and
intraclass correlation coefﬁcient values for six of the seven
dimensions and the overall score exceeded 0.70. Statistically
signiﬁcant differences (P < 0.01) were observed on all
ESPRINT-28 dimensions and the overall score between
patients with mild (mean overall score 1.97, SD 0.99), mod-
erate (mean overall score 2.78, SD 0.88), and severe AR
(mean overall score 3.89, SD 0.87). Patients with persistent
AR had worse scores (P < 0.05) on all dimensions than
patients with intermittent AR. Correlations between the
ESPRINT-28 and the RQLQ were generally as expected.
Effect sizes for score changes between the two study visits
ranged from 0.96 to 1.76 for individual dimensions and the
overall score.
Conclusions: This new, Spanish-developed instrument to
measure HRQOL in AR patients has shown good reliability,
validity, and sensitivity to change. It has also proved easy to
use and administer.
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Introduction
Allergic rhinitis (AR) is a common condition affecting
approximately 10% to 25% of the population world-
wide, and its prevalence is increasing [1,2]. The costs
of the illness are high, both in terms of direct and
indirect cost [3], and AR has a substantial impact on
patients’ quality of life [4–6].
Health-related quality of life (HRQOL) is usually
deﬁned as a multidimensional concept encompassing
the physical, mental, and social components associated
with an illness or its treatment [7]. When assessing
HRQOL, the aim is usually “to measure not only the
actual functional capability, but also the individual’s
perceptions of the impact of these abilities or disabili-
ties on his or her life” [7].
Both generic [8,9] and disease-speciﬁc [10–13]
instruments have been used to evaluate the impact
of AR and its treatment on patients’ HRQOL. Such
instruments are useful for assessing treatment efﬁcacy
in clinical trials, for measuring the burden of disease in
epidemiological studies, or as monitoring tools in clini-
cal practice [14]. Nevertheless, none of the instruments
used or developed to date have explicitly taken into
account the concerns and views of Spanish-speaking
AR patients, nor have they explored the structure of
the HRQOL concept in AR patients in Spain. In fact,
only one disease-speciﬁc instrument––the Rhinocon-
junctivitis Quality of Life Questionnaire (RQLQ)—has
been adapted and validated for use in Spain [15].
As the relevance and structure of the HRQOL
concept may differ across countries and cultures [16],
there is no guarantee that HRQOL-related issues
which are important to AR patients in Canada or the
United States, for example, will be equally relevant
to patients in Spain. It has been suggested that, as a
minimum, further study of the HRQOL construct
across countries and cultures is warranted, and that
development of locally relevant instruments may be
advisable [17]. In the case of AR, differences in behav-
ior patterns, geographic and climatic conditions, and
risk factors may inﬂuence the relevance of question-
naire content. Cultural aspects may also inﬂuence the
way a person lives with a disease and the way patients
react to a disease psychologically and emotionally. For
example, a recent study has shown that fatalism was
associated with lower social functioning in Hispanic
women with coronary heart disease [18] while another
recent study has shown that the degree to which psy-
chosocial aspects impact on HRQOL scores varied
substantially between breast cancer patients from
Germany, Japan, and Korea [19]. Likewise, one of
the most widely used HRQOL measures in AR, the
RQLQ, was developed almost 15 years ago, and
patients’ views on what is important about the disease
and its treatment may have changed since its develop-
ment. Finally, the techniques for the development of
HRQOL measures have also improved over time, and
it may be possible to improve on the psychometric
performance of existing instruments.
The aim of the present study was therefore to
develop an instrument to measure HRQOL in patients
with AR, which would take into account issues of
importance to Spanish patients with AR, which would
be suitable for use in clinical studies, and which might
improve on the psychometric performance of existing
instruments.
Patients and Methods
The study consisted of three main phases: item genera-
tion, item reduction and questionnaire formatting, and
validation of the ﬁnal version of the questionnaire. An
outline of the study is provided in Figure 1.
Item Generation
Questionnaire content was developed from a literature
review, consultations with clinical experts and experts
in the development and use of patient-reported out-
comes (PRO) measures, and focus groups with AR
patients. The literature review, which was extensive
but nonsystematic, was performed to identify instru-
ments already developed to measure the HRQOL of
AR patients and to identify issues of relevance in
the construction of the new instrument. Databases
reviewed included MEDLINE and the Índice Médico
Español. The consultation with experts was in the
form of a structured brainstorming technique, and was
designed to obtain expert views on potential content,
uses, and characteristics (such as length, mode of
administration, and scoring) of the questionnaire.
Experts attending the meeting included allergy and ear,
nose and throat (ENT) specialists and experts in the
development of PRO measures.
Four focus groups with AR patients were performed
in Barcelona, Madrid, Bilbao, and Seville. A semistruc-
tured script, developed from the literature review and
consultations with experts, was used to guide discus-
sions. Focus groups included ﬁve to seven patients,
with a wide range of sociodemographic and clinical
characteristics. All focus group discussions were tape-
recorded and transcribed. Content analysis of the tran-
scribed texts was performed by two of the study group
investigators (EB, MH) and a consensus reached on
which items should go forward to the next stage.
Potential items for inclusion in the questionnaire were
reviewed by three of the study group members (AV, EB,
MH), who rejected items that were ambiguous, difﬁ-
cult to understand, redundant or irrelevant.
Item Reduction and Questionnaire Formatting
To identify items for inclusion in the ﬁnal version of
the questionnaire, the 58 items in the item pool were
administered to a sample of 400 patients with inter-
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mittent AR (IAR) or persistent AR (PAR) in an obser-
vational, cross-sectional, multicenter study. For all
items in the pool, patients rated both the frequency
and importance of each item on 5-point scales ranging
from “Never” to “Always” and “Not at all impor-
tant” to “Very important.” The time period referred to
was the last 2 weeks. Other variables measured in this
phase of the study included age, sex, level of education,
type of AR, time since diagnosis, symptom severity,
and type of treatment for AR. AR was deﬁned as
intermittent when symptoms occurred less than 4 days
per week or less than 4 weeks, and as persistent when
symptoms occurred more than 4 days per week or
more than 4 weeks [1].
Psychometric analyses to reduce the number of
items included: 1) analysis of missing responses (ex-
clusion of items with more than 10% of missing
responses); and 2) response distribution (items in
which more than 60% of respondents checked the
same response category were excluded). Clinimetric
analysis was based on analysis of frequency and impor-
tance scores with the product of the mean frequency
and importance scores being obtained, and items
ranked according to this product. Only the 30 top
ranked items were retained for further analysis. In
addition, Rasch analysis, a form of Item Response
Theory analysis [20], was used to eliminate any
remaining items that performed poorly in terms of inﬁt
and outﬁt values. The ﬁnal phase of item selection was
a meeting of the expert committee to review the item
selection process, and determine whether further
reduction was required or whether items eliminated in
the preceding analysis should be retained on clinical or
other grounds.
When item selection was complete, exploratory
factor analysis was performed and internal consistency
coefﬁcients (Cronbach’s alpha) were obtained for the
dimensions identiﬁed as well as for the overall scale.
Validation Study
In order to determine the new questionnaire’s reliabil-
ity, validity, and sensitivity to change, a prospective,
observational study was performed between March
and August 2004 in the allergy and ENT departments
of 27 Spanish hospitals. Each center consecutively
included patients with the following characteristics: 1)
ambulatory patients aged more than 18 years; 2) with
a diagnosis of IAR or PAR; and 3) who were symp-
tomatic at the time of inclusion in the study. The study
aimed to include a total of 210 patients; approximately
33% of patients completed the questionnaire on one
occasion and the remainder completed the question-
naire on two occasions, 2 to 4 weeks apart, to assess
test–retest reliability and sensitivity to change. All
patients provided informed consent to participate in
the study and the study was approved by the Ethics
Committee of the Hospital Clínic i Provincial in
Barcelona.
Literature review Focus groups Expert metaplan
Item reduction phase (n=400
patients)
 First revision – elimination of 
redundant, ambiguous or difficult-to-
understand items 
Validation study
(n =210 patients)
Definitive 28-item 
version obtained
Generation of 69 
potential items
Initial item pool: 58 
items
Figure 1 Development and validation process
for the ESPRINT questionnaire.
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Patient assessments were performed on inclusion in
the study, and again after 2 to 4 weeks. Data were
collected on sociodemographic (sex, age, and educa-
tional level) and clinical characteristics (time since diag-
nosis, type and severity of AR according to the Allergic
Rhinitis and its Impact on Asthma Initiative [ARIA]
guidelines [1], presence and type of comorbidities,
treatments for AR, and symptom intensity). AR
symptom intensity was measured using the Total
Symptom Score (TSS4), a widely used instrument in
clinical trials in AR which is deﬁned as the sum of nasal
symptoms of obstruction, rhinorrhea, itch, and sneeze.
Each of these is scored on a scale from 0 to 3 resulting
in a TSS4 score ranging from 0 (no symptoms) to 12
(maximum symptom intensity [21,22]. To be included,
patients had to score at least three points on the TSS4.
The new questionnaire was self-administered along-
side the Rhinoconjunctivitis Quality of Life Question-
naire (RQLQ) [10,15] and the Medical Outcomes
Study 12-Item Short-Form Health Survey (SF-12) [23].
The RQLQ consists of 28 items in seven dimensions:
Sleep (3 items), Non–hay fever symptoms (7 items),
Practical problems (3 items), Nasal symptoms (4
items), Eye symptoms (4 items), Activities (3 items),
and Emotions (4 items). The items in the “Activities”
dimension are individualized, which means that the
patient should choose the three dimensions which are
most affected by AR. Responses to the individual items
are on a 7-point ordinal scale, and scores are provided
by dimension and overall, on a 0–6 scale where 0
represents good HRQOL and 6 represents poor
HRQOL. The instrument has been adapted and vali-
dated for use in Spain [15].
The SF-12 [23] is a shortened version of the 36-item
health survey, which has been adapted and validated
for use in Spain [24]. The SF-12 provides a measure of
physical (physical component summary [PCS]) and
mental health (mental component summary [MCS]),
with lower scores indicating worse health status. All
scores were calculated using standard scoring algo-
rithms for the Spanish population, which yield a mean
score of 50 and a SD of 10 in the general population
[23].
A health status transition item was self-
administered at the second visit to assess changes in
health status perception from the ﬁrst visit. Patients
answered on a Likert-type ordinal scale with 13
response options ranging from “have greatly
improved” to “have greatly worsened.” The results
were used in the analysis of test–retest reliability and
sensitivity to change.
Patients were also asked to rate the new question-
naire’s ease of use on a scale ranging from “Very
difﬁcult to complete” to “Very easy to complete,” and
the time taken to complete the questionnaire was
recorded. Other variables measured included age, sex,
level of education, time from diagnosis, presence and
type of comorbidities (particularly asthma and con-
junctivitis) and whether the patient was currently
receiving treatment for AR.
Statistical Analysis
The questionnaire’s feasibility was assessed by exam-
ining responses to the ease of use question, and the
time taken to complete the questionnaire. The number
and percentage of missing responses was also taken
into account by estimating the number and proportion
of patients with at least one missing response, and
maximum number of missing responses per item.
The distribution of the overall and dimension scores
was analyzed by calculating mean scores, standard
deviations, observed score ranges, and ﬂoor and ceiling
effects (the proportion of patients with the worst and
best possible scores, respectively) for the overall score
and for each dimension of the new questionnaire.
The instrument’s internal consistency was assessed
by estimating Cronbach’s alpha coefﬁcients for indi-
vidual dimensions and the overall score at baseline.
The 2- to 4-week test–retest reliability was assessed by
calculating the intraclass correlation coefﬁcient (ICC)
between visits in patients who did not report any sig-
niﬁcant change on the health status transition item.
Known groups validity was tested by determining
whether the instrument was able to discriminate
between patient groups likely to differ in HRQOL:
different degrees of AR severity, with and without
comorbidities, groups with IAR and PAR. AR severity
was classiﬁed empirically as mild if patients scored 3 to
6 points on the TSS4, moderate if they scored 7 to 9
points, and severe if they scored 10 to 12 points.
Patients with PAR were also expected to report worse
HRQOL than patients with IAR [25].
Convergent validity was tested by estimating Spear-
man correlations between scores on the SF-12 PCS and
MCS, scores on the RQLQ and scores on the indi-
vidual dimensions and overall score of the new ques-
tionnaire. Correlations were expected to be higher
between the new questionnaire and the RQLQ, as both
are disease-speciﬁc, than between the new question-
naire and the SF-12. Similarly, correlations between
dimensions measuring similar content in the two
disease-speciﬁc questionnaires (e.g., dimensions mea-
suring psychological and emotional impact) were
expected to be higher than those between dimensions
measuring dissimilar content (e.g., the “Practical prob-
lems” dimension on the RQLQ and the “Sleep”
dimension on the new questionnaire). A series of
hypotheses were developed regarding where the
highest correlations were likely to be seen between
dimensions on the two questionnaires.
Sensitivity to change was assessed by calculating the
effect size (i.e., the standardized mean score change)
and standardized response mean (SRM), in the sub-
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group of patients who reported a “small improve-
ment” or greater on the health status transition item.
Effect size values of about 0.2 were considered to
represent a small change, values of about 0.5 a mod-
erate change, and values of about 0.8 or higher a large
change in the attribute of interest [26]. The SRM was
calculated by dividing the mean change in score by the
standard deviation of the change scores between the
two study visits [27].
Results
Item Generation
The literature review identiﬁed 11 instruments which
had previously been designed to measure AR or related
illnesses, ranging from 14 to 31 items in length. Rec-
ommendations from the expert consensus meeting
concerning the characteristics of the HRQoL question-
naire included that it should be self-administered, easy
to score, and include basic symptoms. The focus group
sessions included 27 AR patients and generated 69
potential items. After elimination of items that were
ambiguous, difﬁcult to understand, redundant or irrel-
evant, an initial pool of 58 items was produced. This
was the version administered to 400 patients for
further item reduction using psychometric and clini-
metric methods.
Item Reduction and Questionnaire Formatting
After administration of the 58 remaining items to
respondents, a further four items were removed
because more than 60% of respondents used the same
response option, 24 items were eliminated because
they scored lowest on the impact score, and four items
were removed because they had inﬁt or outﬁt values
more than 1.30 in the Rasch analysis. On the basis of
clinical recommendations, however, one of these items
was retained, giving a total of 27 items distributed in
seven dimensions (Nasal symptoms, Non-nasal symp-
toms, Energy/vitality, Activities of daily living [ADL],
Environmental aspects, Sleep, and Psychological
impact) as well as an additional question on overall
health related to AR. Responses are on a 5-point Likert
scale and the questionnaire produces both an overall
score and a score for each dimension, which are cal-
culated from the mean of all items in the scale, or in
each dimension, respectively. Lower scores indicate
better health status and higher scores indicate worse
health status. The questionnaire was called the
ESPRINT-28 (Cuestionario ESPañol de Calidad de
Vida en RINiTis). Item frequency and importance
scores in the item reduction stage of the study are
shown in Table 1.
Validation Study
In the validation study, evaluable responses were avail-
able for a total of 206 patients at the ﬁrst visit. Patient
characteristics are shown in Table 2. The study sample
was relatively young (mean age 32.3 years, SD
9.7 years), 62% were women, and the educational
level was generally high (69% had completed second-
ary or university level education). Of the total sample,
65.5% of patients were receiving treatment for AR at
the baseline visit, and 49% had PAR. Using the ARIA
classiﬁcation, AR was classiﬁed as moderate/severe in
96.6% of cases.
In terms of feasibility, only one patient had a
missing response on the ESPRINT-28 at the baseline
visit, and mean (SD) time to complete the question-
naire was 7.1 (5.4) minutes. The questionnaire was
considered easy or very easy to answer by 89.3% of
patients.
Table 3 shows the score distributions, ﬂoor and
ceiling effects, internal consistency, and test–retest
reliability coefﬁcients for the questionnaire. Floor and
ceiling effects were negligible (<15%) in all dimen-
sions and for the overall score. The highest ﬂoor or
ceiling effect was seen on the “Energy/vitality” dimen-
sion, which had a ceiling effect of 14.1%. Cronbach’s
alpha and ICC values were more than 0.70 for the
overall score and for all dimensions, except for the
dimension of “Nasal symptoms” which had an ICC
value of 0.63.
Table 4 shows the results of testing the known
groups’ validity of the ESPRINT-28. Patients with
more severe AR symptoms had statistically signiﬁcant
(P < 0.01) worse (higher) scores on all ESPRINT-28
dimensions and the global score. Score differences
between patients with mild AR and those with severe
AR were in the region of two points on the 6-point
scale in all dimensions. Patients with PAR also had
statistically signiﬁcant (P < 0.01) worse scores than
IAR patients on all dimensions and on the overall
score, with a difference between the groups of approxi-
mately 0.5 to 1.0 points. Patients with comorbidities
reported slightly worse HRQOL on the “Non-nasal
symptoms” and “Energy/vitality” dimensions than
patients without reported comorbidities (mean scores
of 2.77 vs. 1.90 and 2.55 vs. 1.84, respectively), but
there were no statistically signiﬁcant differences
between these two groups on the other dimensions.
Table 5 shows the results of testing the convergent
validity of the ESPRINT-28 by estimating correlations
between ESPRINT-28 dimension and overall scores,
and the RQLQ and SF-12 mental and physical health
summary scores. As predicted, correlations between
the disease-speciﬁc ESPRINT-28 and the SF-12 PCS
and MCS scores were lower than those between the
overall scores of the two disease-speciﬁc instruments,
with the correlations between the MCS and the
ESPRINT-28 overall score being particularly low. In
the case of the ESPRINT-28 and RQLQ dimension
scores, the pattern of correlations was generally as
expected, with dimensions that measure similar
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content on the two instruments showing stronger cor-
relations than those between dimensions with more
dissimilar content. Eight of the 11 initial hypotheses
made regarding where the highest correlations would
be found, were met. The three exceptions were
observed in the correlation between the ADL dimen-
sions on the two questionnaires, the correlation
between the ESPRINT-28 “Non-nasal symptoms”
dimension and the RQLQ “Other symptoms” dimen-
sion, where a very slightly higher correlation was seen
with the RQLQ “Practical problems” dimension (cor-
relations of 0.48 and 0.50, respectively), and the
correlation between the ESPRINT-28 “Environment”
dimension and the RQLQ “Eye symptoms”
Table 1 Mean frequency and importance scores for 58 items included for item reduction
Ranking Item content
Mean score:
frequency
Mean score:
importance
Mean impact
score
1 Annoyed by rhinitis symptoms 1.87 1.79 4.13
2 Nasal itching and/or repeated sneezing 2.31 2.05 5.45
3 Blocked or stuffy nose 2.42 2.09 5.78
4 Liquid or watery nasal mucus 2.36 2.08 5.78
5 Constantly thinking about nasal symptoms 2.56 2.35 7.23
6 Itchy eyes or having to rub eyes 2.78 2.38 7.93
7 Angry at having to constantly interrupt activities 2.81 2.42 8.12
8 Worried by rhinitis symptoms 2.69 2.57 8.12
9 Slept badly because of rhinitis 3.00 2.50 8.82
10 Woken with a dry mouth or because of dry mouth 2.90 2.66 9.13
11 Felt bitter or weighed down by rhinitis symptoms 2.94 2.62 9.17
12 Worried about not having a handkerchief to hand 2.93 2.61 9.27
13 Had a bad time in closed, airless places 3.01 2.67 9.36
14 Bothered by sunlight or wind 2.95 2.71 9.56
15 Problems at work or uncomfortable at work 3.04 2.70 9.71
16 Watery eyes 3.07 2.81 9.92
17 Bothered by sudden changes of temperature 2.98 2.85 9.93
18 Problems sleeping or getting to sleep 3.27 2.78 10.48
19 Nose red or irritated 3.21 2.92 10.58
20 Woken up or got up at night because of rhinitis 3.31 2.85 10.91
21 Woken up feeling tired or fatigued 3.27 2.98 10.98
22 Bothered by symptoms dining out 3.29 2.94 11.03
23 Red or puffy eyes 3.28 2.96 11.01
24 Tickle in throat or roof of mouth 3.23 3.00 11.30
25 Irritable or bad-tempered because of rhinitis 3.39 2.97 11.43
26 Difﬁculties concentrating 3.38 2.97 11.50
27 Difﬁculty breathing, breathlessness 3.45 2.92 11.52
28 Lack of desire to do anything 3.41 3.02 11.54
29 Bothered by eyes or sensitive to sunlight 3.32 3.15 12.06
30 So tired felt like you would not recover all day 3.47 3.11 12.62
31 Low in spirits 3.52 3.18 12.77
32 Problems doing work around house 3.50 3.23 12.82
33 Poor performance at work 3.66 3.15 12.81
34 Conditions at work make rhinitis worse 3.49 3.27 13.22
35 Worried symptoms will bother or irritate others 3.54 3.26 13.30
36 Make noises in throat to relieve itching 3.48 3.32 13.35
37 Headache 3.72 3.33 13.62
38 Loss of smell or taste 3.55 3.49 13.64
39 Distressed by not having rhinitis medication to hand 3.63 3.37 13.67
40 Avoided heated or air-conditioned places 3.67 3.48 14.20
41 Nasal voice or hoarseness 3.63 3.55 14.23
42 Snored because of rhinitis 3.54 3.57 14.25
43 Embarrassed by constantly blowing nose or sneezing 3.78 3.44 14.59
44 Uncomfortable or embarrassed around others 3.74 3.44 14.61
45 Sleepy during the day because of symptoms 3.78 3.52 14.63
46 Chest tightness or coughing that wakes you at night 3.90 3.41 14.79
47 Rhinitis limits you in doing things you want to do 3.86 3.53 15.21
48 Worried about side effects of rhinitis medication 3.71 3.69 15.31
49 Worried more liable to catch other illnesses 3.92 3.79 16.24
50 Itching in ear 3.96 3.81 16.50
51 No energy to do anything because of rhinitis 4.22 3.85 17.45
52 Embarrassed by physical appearance due to rhinitis 4.15 3.96 17.75
53 Stopped doing daily activities and tasks 4.40 3.81 17.75
54 Bothered by having to explain the problem 4.17 4.16 18.12
55 Missed work or left early because of rhinitis 4.52 3.96 18.75
56 Sexual life affected 4.42 4.15 19.22
57 Slept during day because of rhinitis 4.50 4.33 20.27
58 Don’t like taking rhinitis medication in front of others 4.64 4.58 21.87
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dimension, which was lower than that between the
“Environment” and “Practical problems” dimensions.
Finally, Table 6 shows the results of testing the sen-
sitivity to change of the ESPRINT-28 questionnaire,
among patients reporting an improvement in health
status (n = 74). Effect sizes for all dimensions and the
global score were all close to or greater than 1, with
the largest effect size (1.76) being seen on the “Nasal
symptoms” dimension and the smallest (0.97) on the
dimension of “Energy/vitality.” The SRMs were all
lower than the effect sizes, though the pattern of results
was the same, with the “Non-nasal symptoms” and
“Energy/vitality” dimensions being the least respon-
sive and the “Environment” and “Nasal symptoms”
dimensions and the overall score being the most
responsive.
Discussion
The present study has described the development of a
new questionnaire to measure the impact of AR and its
treatment on patients’ HRQOL with a particular
emphasis on issues and concerns which are relevant to
AR patients in Spain. Data presented demonstrate that
the questionnaire is reliable, valid, and sensitive to
change. The instrument has also proven quick and easy
to complete and generates a negligible level of missing
responses.
The development of the ESPRINT-28 followed rec-
ommended guidelines for the construction and valida-
tion of this type of instrument [27,28]. Considerable
effort was made to include the point of view, at various
stages of the process, of the principal parties interested
in the development and use of this type of instrument,
particularly clinicians and patients. In addition to
being easy to complete, the instrument only requires a
relatively short time to administer (7.1 minutes). In a
recent study to validate a Spanish version of the
RQLQ, the authors reported an administration time
for that instrument of 9.67 (SD 6.25) minutes, though
the version used was the original version of the RQLQ
Table 2 Baseline characteristics of the validation study sample
(N = 206)
Sex (n, %)
Female 133 (64.6)
Age (mean, SD) 33.7 (10.5)
Educational level (n, %)
Primary education 64 (31.1)
Secondary education 81 (39.3)
University education 60 (29.7)
Time from diagnosis (mean, SD) 8.4 (6.5)
Comorbidities (n, %)
Asthma 87 (42.2)
Conjunctivitis 108 (52.4)
In treatment for AR* (n, %) 135 (65.5)
Type of AR† (n, %)
Persistent 101 (49)
Intermittent 105 (51)
Severity of AR† (n, %)
Mild 7 (3.4)
Moderate/severe 199 (96.6)
Total symptom score‡ (mean, SD) 7.4 (2.5)
RQLQ§ (mean, SD)
Global score 2.61 (1.10)
Activity limitations 3.35 (1.36)
Practical problems 3.78 (1.46)
Nose symptoms 3.54 (1.33)
Eye symptoms 2.33 (1.69)
Emotional problems 1.63 (1.34)
Sleep problems 2.01 (1.66)
Other symptoms 2.28 (1.45)
ESPRINT-28|| (mean, SD)
Global score 2.72 (1.17)
Nasal symptoms 3.38 (1.21)
Non-nasal symptoms 2.53 (1.37)
Activities of daily living 2.57 (1.52)
Environmental impact 3.13 (1.47)
Energy/vitality 2.36 (1.71)
Sleep 2.50 (1.72)
Psychological impact 2.56 (1.66)
SF-12¶ (mean, SD)
PCS 47.57 (8.8)
MCS 46.65 (10.7)
*At inclusion.
†According to ARIA guidelines.
‡Scores range from 3 (mild symptoms) to 12 (severe symptoms).
§Global and dimension scores range from 0 (no impairment) to 6 (greatest impairment).
||Overall scores range from 0 (minimum impact in HRQOL) to 5.8 (maximum impact
in HRQOL); dimension scores range from 0 (minimum impact in HRQOL) to 6
(maximum impact in HRQOL).
¶Global and dimension score range from 0 (worse health status) to 100 (better health
status).
AR, allergic rhinitis; MCS, mental component summary; PCS, physical component
summary; RQLQ, Rhinoconjunctivitis Quality of Life Questionnaire.
Table 3 Score distributions, ﬂoor and ceiling effects, internal consistency, and test–retest reliability of the ESPRINT-28 questionnaire
ESPRINT-28
dimensions
Nasal
symptoms
Non-nasal
symptoms
Energy/
vitality ADL Environment Sleep
Psychological
impact
Global
score*
Items (n) 4 5 3 4 3 4 4 28
Mean 3.35 2.44 2.31 2.75 3.24 2.60 2.35 2.73
SD 1.36 1.40 2.08 1.83 1.83 2.07 1.85 1.50
Theoretical range 0–6 0–6 0–6 0–6 0–6 0–6 0–6 0–5.8
Observed range 0.25–6 0–6 0–6 0–6 0–6 0–6 0–6 0.07–5.64
Floor† (%) 1.5 0.5 2.4 1.0 1.9 3.4 2.9 0
Ceiling‡ (%) 0 1.9 14.1 5.3 1.5 7.3 7.3 0
Cronbach’s alpha 0.78 0.79 0.94 0.91 0.79 0.92 0.93 0.95
ICC§ 0.63 0.83 0.89 0.81 0.81 0.89 0.86 0.86
*Includes a general item: “In general, thinking only of your rhinitis and no other illness, how would you say your health is?”.
†Percentage of patients with the worst possible score.
‡Percentage of patients with the best possible score.
§Intraclass correlation coefﬁcient (stability assessed by patient; subgroup of stable patients n = 35).
ADL, activities of daily living; ICC, intraclass correlation coefﬁcient.
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which uses individualized items in the “Activity limi-
tations” dimension, and therefore will be longer to
administer [15]. The authors also reported that 16.9%
of participants had a missing response on at least one
of the questionnaire items, which is higher than the
level of missing responses found in the present study
for the ESPRINT-28.
The ESPRINT-28 also shows good psychometric
characteristics, and meets accepted criteria for use in
clinical studies [27–29]. Floor and ceiling effects,
which can be taken as an indication of whether a
measure will be at least theoretically capable of reﬂect-
ing changes for better or worse, were within acceptable
limits on all dimensions, with fewer than 15% of
Table 4 Known groups validity based on symptom severity, type of AR and presence of comorbidity
ESPRINT-28 dimensions
Nasal
symptoms
Non-nasal
symptoms
Energy/
vitality ADL Environment Sleep
Psychological
impact
Global
score
AR symptom intensity*:
mean (SD)
Mild (n = 79) 2.53 (0.99) 1.83 (1.16) 1.60 (1.50)a 1.78 (1.38) 2.22 (1.28) 1.78 (1.44)b 1.81 (1.43)a 1.97 (0.99)
Moderate (n = 80) 3.52 (0.93) 2.63 (1.25) 2.43 (1.52)a 2.64 (1.29) 3.27 (1.21) 2.42 (1.50)b 2.58 (1.60)a 2.78 (0.88)
Severe (n = 47) 4.55 (0.86) 3.53 (1.21) 3.53 (1.70) 3.77 (1.30) 4.42 (1.10) 3.85 (1.73) 3.79 (1.38) 3.89 (0.87)
P-value All comparisons (mild–moderate, moderate–severe, mild–severe) were signiﬁcant at P < 0.001, except those
marked a and b which were signiﬁcant at P < 0.01 and P < 0.05, respectively
Type of AR: mean (SD)
Intermittent (n = 101) 3.12 (1.24) 2.26 (1.32) 1.91 (1.70) 2.19 (1.54) 2.66 (1.46) 1.95 (1.62) 2.09 (1.62) 2.34 (1.18)
Persistent (n = 105) 3.64 (1.13) 2.79 (1.37) 2.80 (1.63) 2.94 (1.42) 3.59 (1.34) 3.04 (1.65) 3.03 (1.58) 3.11 (1.05)
P-value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
Presence of comorbidities†:
mean (SD)
Without (n = 55) 3.40 (1.37) 1.90 (1.29) 1.84 (1.58) 2.76 (1.64) 2.93 (1.60) 2.16 (1.71) 2.50 (1.71) 2.49 (1.21)
With (n = 150) 3.38 (1.16) 2.77 (1.33) 2.55 (1.73) 2.51 (1.49) 3.21 (1.43) 2.64 (1.72) 2.60 (1.65) 2.82 (1.16)
P-value NS <0.01 <0.01 NS NS NS NS NS
*For this analysis, patients’ symptom intensity was classiﬁed using their TSS4 scores: mild AR = 3–6 points on the TSS4; moderate AR = 7–9 points; severe AR = 10–12 points.
†Asthma or conjunctivitis.
ADL, activities of daily living;AR, allergic rhinitis; NS, not signiﬁcant.
Table 5 Convergent validity of ESPRINT-28 with the RQLQ and SF-12 mental and physical health summary scores
ESPRINT-28
dimensions
Nasal
symptoms
Non-nasal
symptoms
Energy/
vitality ADL Environment Sleep
Psychological
impact
Global
score
SF-12
MCS -0.04 -0.01 -0.26 -0.12 -0.12 -0.08 -0.23 -0.12
PCS -0.36 -0.39 -0.49 -0.50 -0.37 -0.45 -0.40 -0.54
RQLQ
Overall score 0.63 0.64 0.74 0.72 0.71 0.63 0.70 0.86
ADL 0.43 0.36 0.48 0.45* 0.50 0.41 0.46 0.55
Sleep 0.42 0.32 0.51 0.48 0.44 0.86* 0.50 0.64
Other symptoms 0.42 0.48* 0.78* 0.64 0.60* 0.55 0.63 0.74
Practical problems 0.63* 0.50 0.42 0.59 0.59 0.38 0.55 0.66
Nose symptoms 0.76* 0.44 0.48 0.58 0.62* 0.50 0.50 0.69
Eye symptoms 0.31 0.80* 0.40 0.36 0.48* 0.23 0.27 0.50
Emotional impact 0.44 0.41 0.57 0.58 0.49 0.34 0.68* 0.63
*Indicates where the strongest correlations were expected to occur between dimensions. Cells in bold indicate cases in which initial hypotheses were not met.
All correlations were statistically signiﬁcant at P < 0.01.
ADL, activities of daily living; MCS, mental component summary; PCS, physical component summary; RQLQ, Rhinoconjunctivitis Quality of Life Questionnaire.
Table 6 Sensitivity to change of ESPRINT-28 questionnaire, among patients reporting at least a small improvement in health status
(N = 74)
Nasal
symptoms
Non-nasal
symptoms
Energy/
vitality ADL Environment Sleep
Psychological
impact
Global
score
Mean score (SD), visit 1 3.47 (1.16) 2.56 (1.39) 2.29 (1.44) 2.61 (1.47) 3.11 (1.29) 2.34 (1.54) 2.65 (1.54) 2.72 (0.98)
95% CI, visit 1 2.68–4.26 1.98–3.14 1.77–2.81 2.02–3.20 2.40–3.82 1.81–2.87 2.05–3.25 2.10–3.34
Mean score (SD), visit 2 1.43 (1.14) 1.19 (1.12) 0.90 (1.12) 0.91 (1.08) 1.53 (1.13) 0.76 (0.97) 0.77 (1.08) 1.12 (0.90)
95% CI 1.10–1.76 0.92–1.46 0.69–1.11 0.70–1.12 1.18–1.88 0.59–0.93 0.59–0.95 0.86–1.38
Effect size 1.76 0.99 0.97 1.16 1.22 1.03 1.22 1.63
SRM 0.73 0.5 0.5 0.61 0.74 0.61 0.63 0.73
ADL, activities of daily living; CI, conﬁdence interval; SRM, standardized response mean.
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patients at either the maximum or the minimum score
on any of the dimensions or the overall score [30]. The
instrument also shows good internal consistency on all
dimensions and for the overall score and meets the
recommended level of 0.7 for use at group level
[27–29]. The Cronbach’s alpha values obtained for the
overall score and four of the dimensions (Energy/
vitality, ADL, Sleep, Psychological impact) on the new
questionnaire (>0.90) are sufﬁcient to permit their use
at individual level [31]. In terms of test–retest reliabil-
ity, the results were also positive, with only one dimen-
sion (Nasal symptoms) falling below the recommended
threshold of 0.70. This might be expected in this type
of dimension, as nasal symptoms are likely to change
quite substantially in a relatively short period of time,
and we did not adjust for this fact.
The instrument’s content validity was ensured by
the process used in the development of the question-
naire, and particularly by the inclusion of focus groups
of patients with the condition, which included a wide
spread of patient characteristics, in terms of age, sex,
educational level, and clinical characteristics. An effort
was also made to include patients from different parts
of Spain to ensure that the sample was also reasonably
geographically representative. This also probably
helped to broaden the range of opinions collected,
which is important in this type of sampling. It is inter-
esting to note that there are a number of differences
with the RQLQ in terms of content. Speciﬁcally, there
were some differences at dimension level; for instance,
the ESPRINT-28 does not contain any items relating
to practical problems associated with AR, as in the
RQLQ, but does contain items on environmental
aspects, an issue which is not covered in the RQLQ. It
also includes a speciﬁc dimension on “Energy/vitality,”
an aspect which is only covered in the RQLQ within
the “Non–hay fever symptoms” dimension. Likewise,
there were differences at item level, such as the inclu-
sion in the ESPRINT-28 of an item relating to the
impact of AR on eating and dining out, which is an
important aspect of Spanish life.
The analysis of known groups’ validity showed that
the questionnaire discriminated well between groups
with different levels of symptoms, as well as between
patients with PAR and IAR. This is, in fact, one of the
ﬁrst studies to examine differences in quality of life
between patients classiﬁed as having IAR or PAR
according to the new ARIA classiﬁcation scheme [1],
and it appears to conﬁrm the results of an earlier study
which showed that AR symptoms were more severe in
patients with PAR [25]. The fact that most of the
dimensions did not discriminate between patients with
andwithout comorbiditiesmay also be taken as positive
as the instrument is intended to focus on the problems
of AR patients, not patients with other types of illness.
The pattern of correlations between the
ESPRINT-28 and the SF-12 PCS and MCS and the
RQLQ were also generally as expected, thereby con-
ﬁrming the instrument’s convergent validity. Correla-
tions were generally higher with the SF-12 PCS than
with the MCS, suggesting that the main impact of the
illness is on physical rather than on mental domains.
The majority of correlations between dimensions on
the ESPRINT-28 and the RQLQ also met a priori
expectations, with eight of the 11 initial hypotheses
regarding likely correlations being met. This signiﬁes a
strong conﬁrmation of the new questionnaire’s conver-
gent validity. The least expected result was the low
correlation between the ADL dimension on the two
questionnaires. This may be due to the fact that, in the
present study, the nonstandardized version of the
RQLQ was used, whereby patients had to choose
the three activities which were most important to
them, whereas ESPRINT-28 uses closed questions
which focus on the impact on work or study, eating
and dining out, and on whether the condition has
obliged patients to interrupt their daily activities. The
type of activities referred to in the two questionnaires
could therefore be substantially different. The high
correlation between the ESPRINT-28 dimension of
“Energy/vitality” and the RQLQ dimension of “Other
symptoms” is likely due to the fact that approximately
half of the items in the RQLQ “Other symptoms”
dimension refer to aspects related to energy and
vitality.
Finally, the instrument appears to be sensitive to
changes in patients’ health status, with changes on all
of the dimensions represented by effect sizes close to
or greater than 1, which would represent a large effect
size, according to Cohen’s classiﬁcation [26]. In
testing the questionnaire, the same approach as that
employed by Juniper and colleagues was used to test
sensitivity to change, in that patients were asked at
the second study visit whether they had noted any
changes in their health status related with their AR
[10]. The changes are not, therefore, necessarily
related to the effects of any given treatment, and
improvements could be due to the natural progression
of the illness. The effect sizes by dimension for the
RQLQ in the recent validation of the Spanish version
were slightly lower than those observed in the present
study, from 0.76 for the general symptoms dimension
to 1.46 for the “Nasal symptoms” dimension and the
overall score [15]. It would be helpful to test the new
instrument’s ability to detect changes associated with
a particular treatment for AR to determine its poten-
tial usefulness in clinical trials.
One of the limitations of the present study was the
relatively small sample size used in the validation stage
of the study. Although the sample size was sufﬁcient to
test the new instrument’s reliability, validity, and sen-
sitivity to change, it was too small to be able to reliably
generalize the results to a larger population, and
studies in larger samples are needed to conﬁrm the
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instrument’s external validity. Likewise, the sample
was too small to be able to examine the instrument’s
responsiveness in patients according to the amount of
positive or negative change they reported on the health
state transition item, which can be useful in determin-
ing the instrument’s longitudinal validity.
In conclusion, this new instrument, which has been
designed primarily to measure the HRQOL of Spanish
and Spanish-speaking respondents, has shown good
reliability, validity, and sensitivity to change. It has also
proved easy to use and administer and has arguably
improved on some aspects of psychometric perfor-
mance when compared with the RQLQ, which can be
considered the gold standard in the ﬁeld. There are
also differences in content between the new instrument
and the RQLQ which justify the development of this
new instrument. Further studies should concentrate
on obtaining additional information such as the
Minimum Clinically Important Difference, which will
aid in the interpretation of scores.
Source of ﬁnancial support: J. Uriach & Co.
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Appendix A. Validated version of the ESPRINT-28 questionnaire
Below you will ﬁnd some questions about bother caused by rhinitis. Please circle the number which corresponds
to your choice of answer. It is important that you answer all of the questions.
Over the last 2 weeks, how much have you been bothered by each of the following symptoms or situations?
Nasal symptoms Not at all Hardly at all A little Moderately Quite a lot A lot Extremely
1. The sensation of a blocked
or stuffy nose
0 1 2 3 4 5 6
2. Runny nasal mucus, like
water
0 1 2 3 4 5 6
3. Itchy nose or constant
sneezing
0 1 2 3 4 5 6
4. Red or irritated nose 0 1 2 3 4 5 6
Other symptoms Not at all Hardly at all A little Moderately Quite a lot A lot Extremely
5. Watery eyes 0 1 2 3 4 5 6
6. Itchy eyes, or need to rub
eyes
0 1 2 3 4 5 6
7. Red or swollen eyes 0 1 2 3 4 5 6
8. Difﬁculty breathing,
breathlessness or
shortness of breath
0 1 2 3 4 5 6
9. Tickle in the throat or
roof of the mouth
0 1 2 3 4 5 6
Activities of daily living Not at all Hardly at all A little Moderately Quite a lot A lot Extremely
10. Have you felt
uncomfortable at work or
have you had difﬁculties at
work because of your
rhinitis
0 1 2 3 4 5 6
11. Have you been bothered
by rhinitis symptoms when
you’ve been out to eat or
for a drink
0 1 2 3 4 5 6
12. Have you had problems
concentrating on your
work, studies, etc. because
of your rhinitis
0 1 2 3 4 5 6
13. Have you had to
constantly interrupt what
you were doing because of
your rhinitis
0 1 2 3 4 5 6
Environmental aspects Not at all Hardly at all A little Moderately Quite a lot A lot Extremely
14. Have you had a bad time
in closed, airless places,
because of your rhinitis
0 1 2 3 4 5 6
15. Have you been bothered
by sudden changes of
temperature, because of
your rhinitis
0 1 2 3 4 5 6
16. Have you been bothered
by sunlight or the wind,
because of your rhinitis
0 1 2 3 4 5 6
Energy Not at all Hardly at all A little Moderately Quite a lot A lot Extremely
17. Have you woken up tired
or fatigued, because of
your rhinitis
0 1 2 3 4 5 6
18. Have you been so tired
because of your rhinitis
that it seemed like you
would not recover at all
during the day
0 1 2 3 4 5 6
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Appendix A. continued
Over the last 2 weeks, how much have you been bothered by each of the following symptoms or situations?
19. Could you not be
bothered to do anything,
because of your rhinitis
0 1 2 3 4 5 6
Sleep Not at all Hardly at all A little Moderately Quite a lot A lot Extremely
20. Have you had trouble
sleeping or falling asleep,
because of your rhinitis
0 1 2 3 4 5 6
21. Have you woken up with a
dry mouth or have you
woken up because of a
dry mouth, due to your
rhinitis
0 1 2 3 4 5 6
22. Have you woken up or
gotten up in the night,
because of your rhinitis
0 1 2 3 4 5 6
23. Have you slept poorly,
because of your rhinitis
0 1 2 3 4 5 6
Mood Not at all Hardly at all A little Moderately Quite a lot A lot Extremely
24. Have you felt bitter or fed
up due to your rhinitis
symptoms
0 1 2 3 4 5 6
25. Have you found yourself
always thinking about nasal
symptoms
0 1 2 3 4 5 6
26. Have you been more
irritable or in a bad mood
because of your rhinitis
0 1 2 3 4 5 6
27. Have you had a bad time
or felt poorly, because of
your rhinitis
0 1 2 3 4 5 6
28. In general, taking into account only your rhinitis and no other illness, how would you rate you health?
Excellent Very good Good Fair Bad
This version in English of the ESPRINT-28 questionnaire is provided only to give readers an idea of questionnaire content. It is not an ofﬁcial adapted version, and should not be
used in any type of study or in clinical practice.Anyone wishing to use the ESPRINT-28 questionnaire should contact the corresponding author.
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